Growing geriatric populations worldwide who are more prone to musculoskeletal disorders is the major factor driving the growth of the market studied. Additionally, increasing prevalence of pain and spasm conditions, increasing focus on the development of novel drugs for the treatment of spasm and pain, frequent product approvals, and growing number of surgeries are the other factors that are bolstering the market growth. However, side effects associated with the muscle relaxant drugs are acting as a restraining factor to the market growth.
Get a PDF Sample for more detailed market insights: https://www.sdki.us/sample-request-89209
Key Market Trends
Neuromuscular Blocking Agents Segment Holds Significant Share in Muscle Relaxant Drugs Market
Neuromuscular blocking agents are the potent muscle relaxants typically used only during surgery to prevent muscle movement. They are structurally related to acetylcholine, the main neurotransmitter in the body, and they cause muscle relaxation by binding to acetylcholine receptors postsynaptically (preventing acetylcholine from binding). This blocks neuromuscular transmission and causes paralysis of the muscle.
These are of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents), or noncompetitive, depolarizing agents (neuromuscular depolarizing agents).
Cisatracurium, Succinylcholine, Doxacurium, and Rocuronium are the few examples of Neuromuscular blocking agents. In November 2019, Zydus Cadila had U.S.FDA approval for its generic version of muscle relaxant Cisatracurium Besylate Injection with strengths of 10 mg/5 ml and 200 mg/20 ml given before general anesthesia.
North America Dominates the Global Muscle Relaxant Drugs Market
The current growth of the North America Muscle Relaxant Drugs market can be primarily attributed to the increasing prevalence of musculoskeletal disorders. On the other side, the presence of sophisticated healthcare infrastructure, frequent product approvals, the presence of major market players focusing on the development of novel molecules for the treatment of pain, and spasm are also acting as major factors for the growth of the market.
According to Palmer College of Chiropractic commissioned Gallup research study in 2018, Neck and back pain is common among adults in the United States. About two-thirds of US adults (62%) have had neck or back pain. In March 2017, Zydus Cadila received approval from the USFDA to market tizanidine hydrochloride capsules, a muscle relaxant, in the American market.
Related Reports:
Muscle Relaxant Drugs Market Size Insight & Future Assessment for the Period 2022-2031
North America Enhanced Oil Recovery Market Size Inclinations & Development Status Highlighted During Forecast Period 2022-2031
Middle East & Africa Oil & Gas Subsea Umbilicals, Risers and Flowlines (SURF) Market Size Drivers and Key Players Strategies Analyzed 2022-2031
Middle East & Africa Oil & Gas Pipeline Market Size: Industry Development Scenario and Forecast 2022-2031
Middle East & Africa Oil & Gas Pipeline Leak and Theft Detection Market Size Analysis Covering Share, Growth, Trends and Upcoming Opportunities 2022-2031
Middle East & Africa Enhanced Oil Recovery Market Size Qualitative Insights on Application & Outlook By Share, Future Growth and Forecast 2022-2031
GCC Smart Grid Market Size| Latest Innovation, Advance Technology, Top Companies 2022-2031
